Takeda and GSK Challenge Latest Data Linking TZDs To Cardiovascular Events
This article was originally published in PharmAsia News
Takeda and GlaxoSmithKline are disputing the findings of a Canadian study published in the December 12 issue of the Journal of the American Medical Association linking thiazolidinediones to cardiovascular events
You may also be interested in...
TOKYO - Daiichi Sankyo provided a status report to investors during a Feb. 21 research and development update in Tokyo. In particular, company officials responded to investor safety concerns related to two key pipeline drugs - anti-platelet drug prasugrel (CS-747) and rivoglitazone (CS-011), a PPAR agonist for type 2 diabetes
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).